Phyto Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 5.00 M
as on 16-11-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.83 Cr
as on 16-11-2024
- Revenue -12.66%
(FY 2023)
- Profit -36.57%
(FY 2023)
- Ebitda -19.18%
(FY 2023)
- Net Worth 9.38%
(FY 2023)
- Total Assets 10.10%
(FY 2023)
About Phyto Drugs
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.83 Cr.
Pankaj Jain, Trapti Nayak, and Amit Nayak serve as directors at the Company.
- CIN/LLPIN
U24230MP2013PTC030846
- Company No.
030846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Phyto Drugs Private Limited offer?
Phyto Drugs Private Limited offers a wide range of products and services, including Ayurvedic Powder and Medicinal Herbs, Herbal Seeds, Ayurvedic & Herbal Extracts, Plant Extracts, Medicinal Plant, Floral Extract, Herbal Extracts, Cooking Spices and Masala, Whole Spices, Essential & Aromatic Oils.
Who are the key members and board of directors at Phyto Drugs?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Nayak  | Director | 27-May-2013 | Current |
| Pankaj Jain | Director | 01-Mar-2016 | Current |
| Trapti Nayak | Director | 27-May-2013 | Current |
Financial Performance of Phyto Drugs.
Phyto Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.66% decrease. The company also saw a substantial fall in profitability, with a 36.57% decrease in profit. The company's net worth moved up by a moderate rise of 9.38%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phyto Drugs?
In 2023, Phyto Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Aug 2023 | ₹9.50 M | Open |
Others Creation Date: 22 Aug 2023 | ₹5.43 M | Open |
Bank Of India Creation Date: 26 Aug 2014 | ₹1.34 Cr | Open |
How Many Employees Work at Phyto Drugs?
Unlock and access historical data on people associated with Phyto Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phyto Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phyto Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
